U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389512) titled 'Pharmaceutical Management in Targeted Radioligand Therapy' on Jan. 29.
Brief Summary: Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues. This approach is based on the use of radiopharmaceuticals (RPs)-compounds that combine a radioactive isotope with a molecule designed to selectively bind to cancer cells.
TRT has historical roots, dating back to the 1950s with the introduction of radioactive iodine-131. It has long been used for the treatment of thyroid cancers, which require hospitalization for 3 to 5 days in a dedicated, isolate...